Long-Term Metabolic Correction of Phenylketonuria by AAV-Delivered Phenylalanine Amino Lyase

Molecular Therapy - Methods & Clinical Development - Tập 19 - Trang 507-517 - 2020
Rui Tao1, Lin Xiao2, Lifang Zhou1, Zhaoyue Zheng2, Jie Long1, Lixing Zhou2, Minghai Tang1, Biao Dong2, Shaohua Yao1
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
2National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Tài liệu tham khảo

Ho, 2014, Phenylketonuria: translating research into novel therapies, Transl. Pediatr., 3, 49

Scriver, 2001, Hyperphenylalaninemia: phenylalanine hydroxylase deficiency, 1667

Guthrie, 1963, A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants, Pediatrics, 32, 338, 10.1542/peds.32.3.338

Evans, 2014, The micronutrient status of patients with phenylketonuria on dietary treatment: an ongoing challenge, Ann. Nutr. Metab., 65, 42, 10.1159/000363391

Mochizuki, 2004, Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice, Gene Ther., 11, 1081, 10.1038/sj.gt.3302262

Ding, 2006, Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer, Gene Ther., 13, 587, 10.1038/sj.gt.3302684

Rebuffat, 2010, Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria, Hum. Gene Ther., 21, 463, 10.1089/hum.2009.127

Yagi, 2011, Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector, J. Gene Med., 13, 114, 10.1002/jgm.1543

Harding, 2006, Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria, Gene Ther., 13, 457, 10.1038/sj.gt.3302678

Laipis, 2004, Correction of maternal phenylketonuria syndrome in the Pahenu2 missense mutant mouse by r-AAV mediated gene therapy, Mol. Ther., 9, S334

Scriver, 1971, Mutants: consumers with special needs, Nutr. Rev., 29, 155, 10.1111/j.1753-4887.1971.tb07281.x

Koukol, 1961, The metabolism of aromatic compounds in higher plants. IV. Purification and properties of the phenylalanine deaminase of Hordeum vulgare, J. Biol. Chem., 236, 2692, 10.1016/S0021-9258(19)61721-7

MacDonald, 2007, A modern view of phenylalanine ammonia lyase, Biochem. Cell Biol., 85, 273, 10.1139/O07-018

Gámez, 2005, Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria, Mol. Ther., 11, 986, 10.1016/j.ymthe.2005.02.013

Ikeda, 2005, Phenylalanine ammonia-lyase modified with polyethylene glycol: potential therapeutic agent for phenylketonuria, Amino Acids, 29, 283, 10.1007/s00726-005-0218-5

Gámez, 2007, Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria, Mol. Genet. Metab., 91, 325, 10.1016/j.ymgme.2007.04.015

Sarkissian, 2008, Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria, Proc. Natl. Acad. Sci. USA, 105, 20894, 10.1073/pnas.0808421105

Zeile, 2018, Maternal phenylketonuria syndrome: studies in mice suggest a potential approach to a continuing problem, Pediatr. Res., 83, 889, 10.1038/pr.2017.323

Sarkissian, 2011, Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria, Mol. Genet. Metab., 104, 249, 10.1016/j.ymgme.2011.06.016

Gupta, 2018, Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials, EBioMedicine, 37, 366, 10.1016/j.ebiom.2018.10.038

Lubich, 2016, The Mystery of Antibodies Against Polyethylene Glycol (PEG)—What do we Know?, Pharm. Res., 33, 2239, 10.1007/s11095-016-1961-x

Verhoef, 2014, Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics, Drug Discov. Today, 19, 1945, 10.1016/j.drudis.2014.08.015

Wang, 2010, Systematic evaluation of AAV vectors for liver directed gene transfer in murine models, Mol. Ther., 18, 118, 10.1038/mt.2009.246

MacDonald, 2010, The reality of dietary compliance in the management of phenylketonuria, J. Inherit. Metab. Dis., 33, 665, 10.1007/s10545-010-9073-y

Demirkol, 2011, Follow up of phenylketonuria patients, Mol. Genet. Metab., 104, S31, 10.1016/j.ymgme.2011.08.005

Ho, 2008, Optimized adeno-associated virus 8 produces hepatocyte-specific Cre-mediated recombination without toxicity or affecting liver regeneration, Am. J. Physiol. Gastrointest. Liver Physiol., 295, G412, 10.1152/ajpgi.00590.2007

Blau, 2015, Alternative therapies to address the unmet medical needs of patients with phenylketonuria, Expert Opin. Pharmacother., 16, 791, 10.1517/14656566.2015.1013030

Kang, 2010, Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria, Mol. Genet. Metab., 99, 4, 10.1016/j.ymgme.2009.09.002

Le, 1997, Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy, Blood, 89, 1254, 10.1182/blood.V89.4.1254

Dong, 2013, A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy, Nucleic Acids Res., 41, 6609, 10.1093/nar/gkt404

Abou-Hashem, 2019, Induction of sub-G0 arrest and apoptosis by seed extract of Moringa peregrina (Forssk.) Fiori in cervical and prostate cancer cell lines, J. Integr. Med., 17, 410, 10.1016/j.joim.2019.09.004

Thông tin
Thông tin xuất bản

Molecular Therapy - Methods & Clinical Development

Tập 19

507-517

Thông tin tác giả